AllDocs -> cancers

276 CancerFutures – Vol 1 – November 2002 Advocacy The Global Lung Cancer Coalition A number of factors contribute to this unsatisfactory situation, not least the fact that, despite their numbers, few lung can- cer patients are either well enough or survive long enough to fight for their rights or advocate for their fellow sufferers. Moreover, many people see lung cancer as a “self-inflicted” illness, and are therefore less inclined to demand improve- ments in the quality of lung cancer treatment and care than perhaps they do for other types of cancer . It is extremely difficult for lung cancer patients to demand priority status for their dis- ease in the face of this unfortunate attitude. Paradoxically, media interest in the fight against the tobacco industry and promotion of smoking cessation, both vital elements in the fight ...

CancerFutures – Vol 2 – July/August 2003 – © Springer-Verlag France 2003 169 Around the world The International Association for the Study of Lung Cancer An international response to a global scourge By Heine H. Hansen and Bodil Diemer Department of Oncology, The Finsen Center, Copenhagen, Denmark T he International Association for the Study of Lung Cancer – IASLC – was established by a group of individuals from many countries and all disciplines of med- icine in response to growing con- cerns over the increasing incidence of lung cancer . That was in 1972 – more than 30 years ago. Sadly, it seems the concerns of these founding members were all too well grounded. Thanks largely to the rise in tobacco consumption, lung cancer – described in a 1912 medical monograph as“one of the rarest forms of disease” – ...

WHAT YOU SHOULD KNOW ABOUT LUNG CANCER * - Lung cancer is the leading cause of cancer related deaths in both men and women in the United States. According to the American Lung Association, approximately 160,000 people will die of lung cancer this year and there will be approximately 173,770 new cases of the disease. -Cancers that begin in the lung are classified into two major types – non- small cell lung cancer and small cell lung cancer – depending on how the cells look under a microscope. Each type of lung cancer grows and spreads in different ways and each type is treated differently. Non-small cell lung cancer is the most common form of lung cancer and accounts for nearly 80 percent of all lung cancers. It generally grows and spreads more slowly than small cell lung cancer . Small cell lung cancer is less common and accounts for ...

a a l l l l I I r r e e l l a a n n d d c c a a n n c c e e r r s s t t a a t t i i s s t t i i c c s s s s e e c c o o n n d d r r e e p p o o r r t t 1 1 9 9 9 9 8 8 - - 2 2 0 0 0 0 0 0 34 Lung cancer Lung cancer Lung cancer Lung c ancer Lung cancer Lung cancer Lung cancer L ung cancer Lung cancer Lung cancer Lung can cer Lung cancer Lung cancer Lung cancer Lun g cancer Lung cancer Lung cancer Lung cance r Lung cancer Lung cancer Lung cancer Lung cancer Lung cancer Lung cancer Lung cancer Lung cancer Lung cancer Lung cancer Lung c ancer Lung cancer Lung cancer Lung cancer L ung cancer Lung cancer Lung cancer Lung can cer Lung cancer Lung cancer Lung cancer Lun g cancer Lung cancer Lung cancer Lung cance r Lung cancer Lung cancer ...

Diesel Emissions and Lung Cancer : Epidemiology and Quantitative Risk Assessment A Special Report of the Institute’s Diesel Epidemiology Expert Panel Health Effects Institute June 1999 Page 2 The Health Effects Institute, established in 1980, is an independent and unbiased source of information on the health effects of motor vehicle emissions. HEI supports research on all major pollutants, including regulated pollutants (such as carbon monoxide, ozone, nitrogen dioxide, and particulate matter), and unregulated pollutants (such as diesel engine exhaust, methanol, and aldehydes). To date, HEI has supported more than 200 projects at institutions in North America and Europe and published over 100 Research Reports. Consistent with its mission to serve as an independent source of information on the health effects of motor vehicle pollutants, ...

Bulletin on the effectiveness of health service interventions for decision makers NHS Centre for Reviews and Dissemination, University of York JUNE 1998 VOLUME 4 NUMBER 3 ISSN: 0965-0288 Effective HealthCare Management of lung cancer The contents of this bulletin are likely to be valid for around one year, by which time significant new research evidence may have become available. s Lung cancer is the third most common cause of death in the UK. The disease progresses rapidly and the prognosis is usually poor; around 80% of patients die within a year of diagnosis. s Since cigarette smoking is responsible for about 90% of cases of lung cancer , action against smoking should be the primary focus of efforts to improve outcomes. A range of co-ordinated interventions ...

Cancer in Rhode Island 9-1 LUNG CANCER Lung cancer originates in the tissues of the lungs. Most cases of lung cancer can be described by one of two separate categories: small cell lung cancer and non-small cell lung cancer . Small cell lung cancer (about 20% of lung cancer cases), as the name implies, deals with the type of lung cancer with cells that are smaller than the average cancer cell. These small cells rapidly reproduce to form large tumors that can spread to other parts of the body. This type of lung cancer is often associated with smoking or secondhand smoke. The most common type of lung cancer is the slower-growing non-small cell lung cancer (nearly 80% of all cases). This category of lung cancer can be further divided into three subcategories: squamous cell carcinoma, adenocarcinoma, and large cell carcinomas. (RICAN) Lung cancer is the second ...

Understanding Lung Cancer A guide for patients and their families Page 2 2 Index 1. Introductionpage 2 2. What is cancer ? ..page 2 3. What is lung cancer ?page 3 4. What are the major causes of lung cancer ?..page 6 5. What are the symptoms of lung cancer ?.page 6 6. Why is lung cancer often detected at a late stage?..page 7 7. How is lung cancer diagnosed?page 7 8. Staging of lung cancer .page 8 9. What are lymph nodes? ..page 10 10. How is lung cancer treated?.page 11 11. What is radiation therapy?.page 13 12. What is chemotherapy? ..page 13 13. What is palliative care? page 14 14. What is a clinical trial? .page 15 15. What is a practice guideline? ..page 16 16. What about complementary and alternative medicine?..page 18 17. Where can I find more ...

23 Chapter 3: Lung Cancer Overview INTRODUCTION Learning about lung cancer is an important part of preparing for the decisions you will be making about your treatment and aftercare. The more you know about lung cancer , the better position you will be in to make informed decisions and advocate for your own interests. This chapter provides an overview of lung cancer topics including: lung cancer risk factors, how lung cancer develops, grows, and spreads, and types of lung cancers. The information will help you understand other chapters in this book, and your health care providers’ recommendations for your care. WHAT IS LUNG CANCER ? Lung cancer develops when normal lung cells sustain genetic damage that eventually leads to uncontrolled cell proliferation . Like all cancers, lung cancer cells have the ability to invade neighboring tissues and spread or ...

109 Chapter 6: Treatment for Small Cell Lung Cancer INTRODUCTION This chapter provides an overview of treatment for small cell lung cancer (SCLC). Treatment options are presented based on the extent of disease. As you read this chapter, keep in mind that each person’s treatment plan is unique to his or her situation. This chapter provides information to help you discuss your treatment options with your cancer care team. However, it will not provide you with treatment recommendations. Many factors unique to your situation must be taken into account to make these crucial decisions. Only your cancer care team can make treatment recommendations. Ongoing clinical trials are evaluating how best to treat SCLC. This chapter presents current treatment standards at the time of its writing. However, state of the art lung cancer care is constantly evolving. Ask your cancer team about new treatment ...

42 Chapter 4: Lung Cancer Diagnosis & Staging INTRODUCTION The lungs are vital organs. Working with the heart and circulatory system, they provide life-sustaining oxygen and rid the body of carbon dioxide. Normal lungs have a great reserve capacity to meet the body’s need for oxygen across a wide variety of circumstances. The same is true of the heart and circulatory system. This reserve capacity permits cancerous lung tumors to grow for years without compromising lung function. Furthermore, the lungs do not have many nerves to transmit pain messages. Therefore, a cancerous lung tumor can grow for many years without causing any symptoms . Unfortunately, this means that most people are not diagnosed with lung cancer until late in the disease process. Even more unfortunate is the fact that this long period of silent growth gives the cancer time to spread before it ...

MINIMUM DATA SET FOR LUNG CANCER HISTOPATHOLOGY REPORTS Co-ordinators: Dr A R Gibbs, Llandough Hospital, Penarth Dr P DaCosta, Airedale General Hospital These proposals for reporting lung cancer should be implemented for the following reasons: 1 . Certain features of lung cancer (histological type, size, local extent and stage, lymph node status) 1-4 have been shown to be related to clinical outcome. Consequently these features may be important in a) deciding on the most appropriate treatment for particular patients including the need and choice of adjuvant therapy. 5,6 b) providing prognostic information to clinicians and patients. 1 c) monitoring clinical effectiveness of therapeutic trials d) providing accurate data for cancer registration. 2. Decisions about surgical resectability are made following clinical and radiological staging ...

WHAT IS LUNG CANCER ? ––––––––––––––––––––––––––––––––––––––– Lung cancer is a growth of abnormal cells inside the lung . These cells reproduce at a much faster rate than normal cells, growing out of control to form a mass called a tumour. When the abnormal growth begins in the lung , this is known as a primary lung tumour. WHAT ARE THE TWO MAJOR TYPES OF LUNG CANCER ? ––––––––––––––––––––––––––––––––––––––– Cancers that begin in the lungs are divided into two major types - non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) - depending on how the cells look under a microscope. NSCLC generally spreads to distant organs at a slower rate than SCLC. NSCLC is the most common type of lung cancer , accounting for almost 80 per cent of all lung cancers. SOME STATISTICS: ––––––––––––––––––––––––––––––––––––––– ...

Facts for Canadians Lung cancer is the leading cause of all cancer deaths in Canada, with one of the poorest survival rates. Give yourself a fighting chance. 180 Bloor Street West, Suite 904 Toronto, Ontario M5S 2V6 Toll Free 1-877-472-3436 Tel: (416) 538-4874 email: canceradvocacy@on.aibn.com web: www.canceradvocacycoalition.com GLCC exists to promote global understanding of the burden of lung cancer and the right of patients to effective early detection, better treatment and supportive care. They are committed to improving disease outcomes for all. Sponsored by an unrestricted educational grant from AstraZeneca. Facts for Canadians LUNG CANCER TREATMENT _ Treatment of non-small-cell lung cancer consists of various combinations of surgical resection, chemotherapy ...

VOL 9/NO 4, OCT/DEC 2003 • www.ijoeh.com Special Contribution • 397 I thank Dr. Boffetta and co- authors 1 for taking the trouble to answer my critique of their study on lung cancer among man-made vit- reous fibers (MMVF) production workers, 2 a critique that I e-mailed to each one of them as early as Sep- tember–October 2001. (Regret- tably, I never received any response to this attempt to engage Dr. Bof- fetta and co-workers in an informal scientific discussion of their study.) In their letter to the editor, 1 Dr. Boffetta and co-authors declare their surprise that my critique 3 was published in the present journal. Some background information is needed to elucidate why things happened that way: When Dr. Boffetta and co-work- ers first published their study in December ...

RADIATION THERAPY for LUNG CANCER Facts to Help Patients Understand Their Treatment ABOUT ASTRO The American Society for Therapeutic Radiology and Oncology is the largest radiation oncology society in the world. ASTRO's mission is to advance radiation oncology by promoting excellence in patient care, supporting research and distributing research results. LEARNING ABOUT CLINICAL TRIALS The radiation oncology team is always looking for new ways to treat and cure cancer through studies called clinical trials. Today's lung cancer radiation therapy treatments are the result of clinical trials completed in the past proving that radiation therapy kills cancer cells and is safe long term. For more information on clinical trials, please visit the following Web sites: National Cancer Institute www. cancer .gov/clinicaltrials ...

April 10, 2003 A.S. Perkins 785-6843 1 Biology 315b Lecture #2 Chemical Carcinogenesis and Cancer of the Lung Readings Required: Lecture Notes Description of Lung Histology in any Histology Textbook Optional: Kumar, Cotran, and Robbins, Basic Pathology. p 427-433, The respiratory system. Chemical Carcinogenesis: Initiation and Promotion In 1775, the English surgeon Percivall Pott noted a high rate of skin cancer of the scrotum among chimney sweeps. This occupation involved repeated exposure of the sweeps to chimney soot, and Pott was able to make the connection between the exposure and the disease despite the decades-long latent period. At this time, a causal connection between exposure and disease had not been established for any disease, so Pott's observations and conclusions are noteworthy. This represented a novel concept - that cancer could be caused ...

Chemotherapy in Non-Small Cell Lung Cancer : An Update A meta-analysis of randomised trials using individual patient data Protocol C Comparison 3 Surgery + Radiotherapy vs Surgery +Radiotherapy + Adjuvant Chemotherapy Conducted by the Non-Small Cell Lung Cancer Collaborative Group (NSCLCCG) May 2004 Page 2 Protocol C surgery + radiotherapy vs surgery + radiotherapy + chemotherapy NSCLC Collaborative Group Secretariat Comparisons 1, 2 & 7 please contact Meta-analysis Group MRC Clinical Trials Unit 222 Euston Road London NW1 2DA UK Fax: +44 (0)20 7670 4816 Sarah Burdett email: sb@ctu.mrc.ac.uk tel: +44 (0)20 7670 4722 Lesley Stewart email: ls@ctu.mrc.ac.uk tel: +44 (0)20 7670 4724 Richard Stephens email: ...

General Practitioner in Oncology Self-directed Learning Program LUNG CANCER MODULE Page 2 Lung Cancer Case Scenario 1 A 65-year-old man presents with a 6- week history of cough, progressive SOB and a 20-pound weight loss. He has a 50-pack year smoking history and his family doctor orders a chest x-ray and blood work. The chest x-ray shows a left lower lobe mass. A CT scan of the thorax shows mediastinal lymph nodes confined to the left hemithorax. 1. What tests are required to properly stage this patient? 2. Assuming his disease is confined to the chest, what stage is this man’s small cell lung cancer ? 3. How does staging for small cell lung cancer differ from non-small cell lung cancer ? 4. With respect to staging in small cell lung cancer , how would stage be affected if the patient had contralateral supraclavicular ...

M ARY H ORRIGAN C ONNORS C ENTER FOR W OMEN ’ S H EALTH AND G ENDER B IOLOGY P OLICY I SSUES IN W OMEN ’ S H EALTH : L UNG C ANCER AND S MOKING Lung cancer mortality rates among women have increased by 600% since 1950. 1 In 2001, lung cancer was the leading cause of cancer death for women in Massachusetts, surpassing breast cancer , and accounting for 24% of all deaths. The lung cancer mortality rate among women in Massachusetts increased from 43.3 per 100,000 in 1989 to 51.2 in 1998. Although the mortality rate from lung cancer varied significantly ...

Screening for lung cancer is not currently recommended by any major medical professional organization. The U.S. Preventive Services Task Force (USPSTF) gave lung cancer screening a “D” recommendation in both 1985 and 1996, meaning that there were fair-quality data to recommend against screening for lung cancer 1 based largely on 3 negative trials conducted in the United States in the 1970s. Since the last Task Force review, several new studies of lung cancer screening have been reported, and greater attention has been directed toward the limitations of existing literature. This review was conducted to aid the current USPSTF in updating its lung cancer screening recommendation. Lung cancer is the leading cause of cancer -related death among men and women in the United States; in 2003, approximately 171,900 new cases and 157,200 lung cancer -associated ...

Summary of Recommendation The U.S. Preventive Services Task Force (USPSTF) concludes that the evidence is insufficient to recommend for or against screening asymptomatic persons for lung cancer with either low dose computerized tomography (LDCT), chest x-ray (CXR), sputum cytology, or a combination of these tests. I recommendation. The USPSTF found fair evidence that screening with LDCT, CXR, or sputum cytology can detect lung cancer at an earlier stage than lung cancer would be detected in an unscreened population; however, the USPSTF found poor evidence that any screening strategy for lung cancer decreases mortality. Because of the invasive nature of diagnostic testing and the possibility of a high number of false-positive tests in certain populations, there is potential for significant harms from screening. Therefore, the USPSTF could ...

EDITORIAL A Perspective on Cytology of Lung Cancer [Indian J Chest Dis Allied Sci 2004; 46 : 81-83] The dawn of the last century was still early days for carcinoma lung , when it was regarded as an uncommon form of malignancy. A signi- ficant rise in the incidence of lung cancer was noticed at the end of World War I, the occur- rence closely correlated with the degree of atmospheric pollution and density of popula- tion. Besides these, personal habits like cigarette smoking and occupation also had an effect. During the second half of the last century an increase in size and ageing of the population have contributed to the increase in absolute numbers of lung cancer every year. It is presently considered one of the most common and deadly malignancies throughout the world. To date, the public health measures and thera- peutic advances have failed to reverse ...

J R Coll Physicians Edinb 2006; 36: 000–000 © 2006 RCPE CME PN J R Coll Physicians Edinb 2006; 36: 000–000 © 2006 Royal College of Physicians of Edinburgh SESSION 1 THE SCALE OF THE PROBLEM – AND CAN THAT BE CHANGED? Dr D Brewster, Professor H Burns, Professor J Jett At present, there are more than 4,000 new cases of lung cancer and just fewer than 4,000 deaths from lung cancer reported per year in Scotland. However, there does appear to be a decrease in incidence of lung cancer among the male population, and a levelling off in the female population. There is evidence that smoking cessation leads to a substantial and significant reduction in lung cancer risk with 30 years of abstinence leading to a relative risk reduction of 90%. 1 Since it has been shown that 60–70% of smokers want to stop,the emphasis must ...

FOREWORD by Finbarr O’Connell Lung cancer is the leading cause of cancer mortality in Ireland causing approximately 20% of all cancer deaths. Incidence in Irish men has fallen slightly in recent years and is below the EU average, but in Irish women is on the increase and is more than double the EU average. Lung cancer is likely to eclipse breast cancer as the leading cause of cancer mortality in Irish women in the near future and has already done so in some other countries. Unfortunately, despite the enormous burden of disease, the prevailing attitude to lung cancer , even among health care professionals, is one of pessimism, or at worst, absolute nihilism. This reflects poor overall survival rates, even in the minority of patients who present with apparent early-stage disease who are treated with intention to cure. Overall 5-year survival is less than 10% and despite advances in radiotherapy and ...

LUNG Josephine Fleming set a world record as the first lung cancer patient to survive five years after starting gene therapy. A life-long resident of Denton, Texas, Fleming enjoys her eight grandchildren, going places with friends, and making tamales, pralines and peanut brittle. Just the Facts Lung Cancer Smoking is responsible for 87 percent of all lung cancer cases in the United States. Eliminating tobacco use is the key to reducing the impact of this disease. Symptoms Symptoms of lung cancer vary from person to person and may include: • a cough that will not go away and gets worse over time • constant chest pain, or arm and shoulder pain • coughing up blood • shortness of breath, wheezing or hoarseness • repeated episodes of pneumonia or bronchitis • swelling of the neck and face • loss of appetite and/or weight loss ...

A property-based model for lung cancer diagnosis Alma Barranco-Mendoza 1 , Deryck R. Persaud 2 , Verónica Dahl 3 Keywords: cancer diagnosis, biomarkers, molecular targets, logic programming, constraint handling rules, concept formation. 1 Introduction. To this day, lung cancer remains the leading cause of cancer death for both sexes: almost one- third of cancer deaths among men and almost one-quarter among women. [1] Survival rates for lung cancer are low. It is suggested that only about 15% of patients are diagnosed at the early stages. The average 5-year survival rate for patients that are diagnosed early is 48% compared to 15% for those who were diagnosed at the later stages. [2] It is well known that the survival rates can be improved by the early detection of pre-invasive lesions, which are believed to be the possible precursors ...

NMT B B R R I I E E F F S S New Medical Therapies Lung Cancer L ung cancer is the leading cause of cancer deaths worldwide, with an estimated 171,900 new cases of lung cancer and an estimated 157,200 deaths from lung cancer in the U.S. in 2003. Although incidence appears to be decreasing among white and African- American men in the U.S., it continues to rise among both white and African-American women. Each year, lung cancer kills more men than does prostate cancer and more women than does breast cancer . Non-small cell lung cancer (NSCLC), which includes squamous cell carcinoma, adenocarci- noma, and large cell carcinoma, is the most prevalent form of lung cancer . Small cell lung cancer (SCLC), or oat cell cancer , accounts for about 20% of all cases of lung cancer . SCLC metastasizes ...

132 SECTION TWELVE 114. Primary Lung Cancer • 15% overall 5-year survival for all lung cancers –NSCLC stage I: 60–70% 5-year survival –NSCLC stage II: 40% 5-year survival –NSCLC stage III/IV: <15% 5-year survival –Untreated SCLC survival <6 month –Chemotherapy-treated SCLC <10% 5-year survival (however, 50% of patients have an initial positive response) • Complications of unresectable tumors include pleural effusion, post-obstructive pneumonia, airway obstruction, bronchopleural fistula, and metastases • Complications of resected tumors include local or distant recurrence, empyema, bronchopleural fistula, and post-thoracotomy pain • SCLC management is almost exclusively non-surgical –Responds well to combination chemotherapy –Radiation to symptomatic sites for palliation –Prophylactic brain radiation is often used as >80% of patients develop ...